Abstract
Purpose Dynamic contrast-enhanced MR imaging (DCE-MRI) is widely deployed in cancer care and research, but the methods conventionally used to quantify contrast agent kinetics do not account the cross-voxel movement characterized by advection and diffusion. We hypothesized that unbalanced optimal mass transport could be used to quantify and visualize such contrast agent flows across tumor volumes.
Methods We developed a computational fluid dynamics model termed the unbalanced regularized optimal mass transport (urOMT) model. We tested the urOMT on a multi-institutional dataset of 153 longitudinal DCE-MRI scans from 39 breast cancer patients treated with neoadjuvant chemotherapy (NACT.)
Results The urOMT model can quantify dynamic fluid transport properties such as net speed, flux and rates of contrast entering and leaving the tumor (influx and efflux). The urOMT model can also visualize the trajectories and directions of net fluid flows. Quantitative metrics from urOMT exhibited distinct patterns that may be relevant to predicting pathological complete response (pCR) to NACT.
Conclusion The urOMT model can be used to estimate and visualize local fluid flow in DCE-MRI breast cancer images. Model-based estimates of flux, influx and efflux should be tested as potential predictive imaging biomarkers to measure treatment effectiveness in patients treated with NACT. The urOMT model in principle has applicability to other cancer imaging use cases, but this will require further testing.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the NIH Cancer Center Support grant to MSK (P30 CA008748), NIH grant U01 CA154602, R01 CA248192, The Enid A. Haupt Endowed Chair Fund for Medical Physics, The Simons Foundation, and a Breast Cancer Research Foundation grant (BCRF-17-193).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: https://www.cancerimagingarchive.net/collection/qin-breast-dce-mri/ The study 'Multi-Functional Magnetic Resonance Imaging Modalities for Assessment of Breast Cancer Response to Neoadjuvant Chemotherapy' was approved by the IRB of Oregon Health & Science University (#IRB00005492)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding Information This study was supported by the NIH Cancer Center Support grant to MSK (P30 CA008748), NIH grant U01 CA154602, R01 CA248192, The Enid A. Haupt Endowed Chair Fund for Medical Physics, The Simons Foundation, and a Breast Cancer Research Foundation grant (BCRF-17-193).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
https://www.cancerimagingarchive.net/collection/qin-breast-dce-mri/
